LifeVantage Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Umsatz und der Gewinn von LifeVantage werden voraussichtlich um 6.4% bzw. 10.7% pro Jahr zurückgehen, während der Gewinn je Aktie voraussichtlich um 10.8% pro Jahr sinken wird.
Wichtige Informationen
-10.7%
Wachstumsrate der Gewinne
-10.81%
EPS-Wachstumsrate
| Personal Products Gewinnwachstum | 33.6% |
| Wachstumsrate der Einnahmen | -6.4% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 13 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 01
LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.Narrativ-Update • Apr 17
LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.Narrativ-Update • Apr 02
LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.Narrativ-Update • Mar 19
LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.Narrativ-Update • Mar 05
LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.Narrativ-Update • Feb 18
LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.Analyseartikel • Feb 06
Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...Narrativ-Update • Feb 04
LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).Narrativ-Update • Jan 21
LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).Narrativ-Update • Jan 07
LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).Narrativ-Update • Dec 22
LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.Narrativ-Update • Dec 08
LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).Narrativ-Update • Nov 24
LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.Analyseartikel • Nov 14
Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...Analyseartikel • Nov 04
We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Sep 30
It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...Analyseartikel • Sep 05
LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...Seeking Alpha • Jul 21
The LifeVantage Advantage: High Retention, High Returns
Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking AlphaAnalyseartikel • May 13
Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...Analyseartikel • May 02
What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...
Neues Narrativ • Feb 14
New Initiatives Will Drive MindBody GLP-1 System's Future Success
Expansion into international markets and enhanced supply chain capacity are expected to drive significant revenue growth and stabilize future sales.Analyseartikel • Feb 09
LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.04
LifeVantage Corporation's ( NASDAQ:LFVN ) investors are due to receive a payment of $0.04 per share on 17th of March...Analyseartikel • Feb 07
LifeVantage Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a mediocre week for LifeVantage Corporation ( NASDAQ:LFVN ) shareholders, with the stock dropping 10% to...Seeking Alpha • Feb 06
LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity
Summary LifeVantage Corporation's Q2 FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8.7 million represented a new multi-year high. However, elevated commissions and incentive expenses impacted profitability, thus resulting in a rather mediocre Adjusted EBITDA margin of 9.6%. While the current expense headwinds are expected to abate going into FY2026, I have lowered Adjusted EBITDA estimates and reduced my price target from $31 to $27. While investor disappointment is understandable, I consider the post-earnings sell-off a buying opportunity. That said, with the story being largely tied to the persistent success of a single blockbuster product, the investment thesis is not without risks. Read the full article on Seeking AlphaAnalyseartikel • Feb 05
LifeVantage Corporation (NASDAQ:LFVN) Looks Just Right With A 33% Price Jump
Despite an already strong run, LifeVantage Corporation ( NASDAQ:LFVN ) shares have been powering on, with a gain of 33...Analyseartikel • Feb 01
What Is LifeVantage Corporation's (NASDAQ:LFVN) Share Price Doing?
LifeVantage Corporation ( NASDAQ:LFVN ), is not the largest company out there, but it led the NASDAQCM gainers with a...Analyseartikel • Dec 20
Market Participants Recognise LifeVantage Corporation's (NASDAQ:LFVN) Earnings Pushing Shares 31% Higher
LifeVantage Corporation ( NASDAQ:LFVN ) shares have continued their recent momentum with a 31% gain in the last month...Analyseartikel • Dec 16
LifeVantage (NASDAQ:LFVN) Will Be Hoping To Turn Its Returns On Capital Around
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 6/30/2028 | 165 | 4 | N/A | N/A | 1 |
| 6/30/2027 | 178 | 5 | 11 | 16 | 3 |
| 6/30/2026 | 184 | 5 | 7 | 15 | 3 |
| 3/31/2026 | 195 | 6 | 4 | 7 | N/A |
| 12/31/2025 | 210 | 8 | 2 | 4 | N/A |
| 9/30/2025 | 229 | 10 | 9 | 10 | N/A |
| 6/30/2025 | 229 | 10 | 11 | 12 | N/A |
| 3/31/2025 | 222 | 9 | 12 | 13 | N/A |
| 12/31/2024 | 212 | 7 | 13 | 14 | N/A |
| 9/30/2024 | 196 | 4 | 5 | 7 | N/A |
| 6/30/2024 | 200 | 3 | 10 | 12 | N/A |
| 3/31/2024 | 205 | 4 | 11 | 13 | N/A |
| 12/31/2023 | 211 | 3 | 11 | 14 | N/A |
| 9/30/2023 | 213 | 3 | 9 | 13 | N/A |
| 6/30/2023 | 213 | 3 | 4 | 7 | N/A |
| 3/31/2023 | 210 | -1 | 3 | 6 | N/A |
| 12/31/2022 | 206 | -1 | 1 | 3 | N/A |
| 9/30/2022 | 205 | 0 | 4 | 6 | N/A |
| 6/30/2022 | 206 | 3 | 6 | 8 | N/A |
| 3/31/2022 | 210 | 9 | 12 | 14 | N/A |
| 12/31/2021 | 212 | 10 | 13 | 16 | N/A |
| 9/30/2021 | 219 | 14 | 15 | 18 | N/A |
| 6/30/2021 | 220 | 13 | 13 | 16 | N/A |
| 3/31/2021 | 225 | 12 | 13 | 17 | N/A |
| 12/31/2020 | 229 | 12 | 15 | 17 | N/A |
| 9/30/2020 | 232 | 12 | 18 | 21 | N/A |
| 6/30/2020 | 233 | 12 | 16 | 18 | N/A |
| 3/31/2020 | 230 | 12 | 13 | 16 | N/A |
| 12/31/2019 | 230 | 12 | N/A | 17 | N/A |
| 9/30/2019 | 227 | 8 | N/A | 12 | N/A |
| 6/30/2019 | 226 | 7 | N/A | 18 | N/A |
| 3/31/2019 | 224 | 7 | N/A | 16 | N/A |
| 12/31/2018 | 218 | 6 | N/A | 16 | N/A |
| 9/30/2018 | 210 | 6 | N/A | 13 | N/A |
| 6/30/2018 | 203 | 6 | N/A | 13 | N/A |
| 3/31/2018 | 200 | 3 | N/A | 10 | N/A |
| 12/31/2017 | 194 | 1 | N/A | 6 | N/A |
| 9/30/2017 | 194 | 1 | N/A | 6 | N/A |
| 6/30/2017 | 199 | 2 | N/A | 7 | N/A |
| 3/31/2017 | 202 | 4 | N/A | 4 | N/A |
| 12/31/2016 | 213 | 5 | N/A | 3 | N/A |
| 9/30/2016 | 216 | 6 | N/A | 6 | N/A |
| 6/30/2016 | 207 | 6 | N/A | 6 | N/A |
| 3/31/2016 | 199 | 4 | N/A | 10 | N/A |
| 12/31/2015 | 188 | 3 | N/A | 14 | N/A |
| 9/30/2015 | 184 | 3 | N/A | 11 | N/A |
| 6/30/2015 | 190 | 7 | N/A | 13 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: LFVNFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-10.7% pro Jahr).
Ertrag vs. Markt: LFVNFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-10.7% pro Jahr).
Hohe Wachstumserträge: LFVNFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.
Einnahmen vs. Markt: LFVNDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-6.4% pro Jahr).
Hohe Wachstumseinnahmen: LFVNDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-6.4% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LFVN in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/15 23:36 |
| Aktienkurs zum Tagesende | 2026/05/15 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/06/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
LifeVantage Corporation wird von 5 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |